The findings from the Women’s Health Initiative are in line with recent guidelines for the primary prevention of stroke.

Looking toward approval in the US, larger studies with careful hemodynamic data will be needed, says Martin Leon.

With the new analysis, researchers rule out embolic protection for stroke prevention in TAVI, but not everybody has given up.

These exploratory results from the FINEARTS-HF trial require confirmation in dedicated trials. REDEFINE-HF is underway.

Researchers say the data underscore the need for more aggressive surveillance of patients, even when AS is moderate AS.

The observed treatment rates, which “absolutely can go higher,” wouldn’t be acceptable for serious cancers, Stephen Greene ...

A sex gap seen in quality of life deserves further scrutiny, but the DISCHARGE trial data are still reassuring, says Maros ...

While the results bolster efficacy, questions remain about high costs and other issues with the ATTR-CM therapies.

Current guidelines support culprit-only PCI in these cases, but the “hypothesis-generating” results suggest taking a closer ...

The results have implications not only for resource-limited parts of the world, but also for wealthier countries, one expert ...

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

A decade on, there’s less revascularization with FFR-guided complete vs culprit only PCI, but COMPLETE-2 is on the way.